Summary
Quest Diagnostics Incorporated (DGX) filed an 8-K on October 28, 2022, to disclose significant changes to the compensation package for Mr. Davis upon his promotion to Chief Executive Officer and President, effective November 1, 2022. These changes reflect his expanded responsibilities and aim to align his incentives with the company's performance and long-term value creation. The updated compensation includes a substantial increase in base salary, a higher target for annual incentives, and revised severance plan participation. Additionally, Mr. Davis will receive enhanced benefits such as transportation allowances and relocation assistance. A significant equity grant valued at $5,000,000, comprised of performance shares and restricted stock units, underscores the company's commitment to retaining and motivating its new CEO.
Key Highlights
- 1Mr. Davis's base salary increased to $1,100,000 annually, effective November 1, 2022.
- 2Target annual incentive increased to 150% of base salary, with pro-rata adjustments for 2022.
- 3Mr. Davis moved to Schedule A Participant status in the Executive Officer Severance Plan.
- 4New benefits include a transportation allowance up to $175,000 annually and relocation benefits up to $125,000.
- 5A $5,000,000 equity grant was awarded, consisting of 60% performance shares and 40% restricted stock units.
- 6Share ownership guidelines for Mr. Davis increased from four to six times his annual base salary.
- 7The equity grant has performance goals aligned with other senior executives and specific vesting schedules for RSUs and performance shares.